Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
163
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

202
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
202
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electronic pharmaceutical claims data for medication reconciliation processes.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Retrospective Bayesian Reanalysis of Single Gentamicin Concentrations: A Neonatal Case Series.

Medicines (Basel, Switzerland)·2025
Same author

Comparison of Students' Self-Assessment and Simulated Patient Assessment in a Patient Counseling Evaluation and Perceived Importance of Communication Skills.

Pharmacy (Basel, Switzerland)·2022
Same author

An Updated National Profile of Curriculum Committees at US Schools and Colleges of Pharmacy.

American journal of pharmaceutical education·2021

Related Experiment Video

Updated: Jul 2, 2025

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

1.3K

Two Cases of Vancomycin-Induced Neutropenia.

Kirsten Ganaja1, Sarah Scoular2, Staci Hemmer2

  • 1Dignity Health Marian Regional Medical Center, Santa Maria, CA 93454, USA.

Pharmacy (Basel, Switzerland)
|February 23, 2024
PubMed
Summary

Vancomycin-induced neutropenia is a rare adverse drug reaction. Two cases highlight the need for further research into its incidence and risk factors.

Keywords:
adverse drug reactionsleukopeniaside effectswhite blood cell

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.4K
Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection
09:09

Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection

Published on: March 14, 2019

9.0K

Related Experiment Videos

Last Updated: Jul 2, 2025

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

1.3K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.4K
Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection
09:09

Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection

Published on: March 14, 2019

9.0K

Area of Science:

  • Pharmacology
  • Hematology
  • Infectious Diseases

Background:

  • Vancomycin-induced neutropenia incidence is estimated at 2-8% in hospitalized patients.
  • Limited data exists due to small observational studies and varying patient characteristics.
  • Generalized conclusions are difficult to ascertain from current literature.

Observation:

  • Two cases of vancomycin-induced neutropenia are presented.
  • A 50-year-old male with a gluteal abscess and a 51-year-old female with lumbar osteomyelitis developed neutropenia.
  • Neutropenia resolved within 2 days of vancomycin discontinuation in both patients.

Findings:

  • Vancomycin-induced neutropenia is considered uncommon.
  • Two cases occurred within a 3-month period at the same facility.
  • Prolonged vancomycin exposure is a likely cause.

Implications:

  • Further studies are needed to determine the true incidence of vancomycin-induced neutropenia.
  • Identifying risk factors for this adverse drug reaction is crucial.
  • Enhanced monitoring may be warranted in patients receiving prolonged vancomycin therapy.